GET DAILY SIGNALSWhy Is Carlsmed (CARL) Stock Down -6.07% Today?
Key Takeaways
- CARL shares fell roughly 6% intraday, trading near $14.39, extending the prior session's 4.79% decline.
- The slide comes days before the company's third-quarter earnings report, scheduled for Tuesday, November 10, after the market close.
- Profit-taking after a strong multi-month run and a recent insider sale disclosure added to selling pressure.
- Technically, the stock broke below its 50-day moving average, inviting momentum-driven selling in a lightly traded small-cap.
- Traders are watching next week's Q3 results, surgeon-adoption metrics, and any updates to full-year guidance.
- For more detail on valuation, quarterly results, and outlook, explore the Price Targets, Earnings, and Forecast pages.
- To see how AI-driven trading systems are positioned, visit Trending AI Robots.
Opening Summary
Carlsmed, Inc. (CARL), a commercial-stage medical technology company that develops AI-enabled personalized spine surgery solutions under its aprevo platform, moved sharply lower in Thursday's session. The stock fell approximately 6.07% to trade near $14.39, down from a prior closing price of $15.32. The decline confirmed a second consecutive down day and pushed shares decisively below their 50-day moving average of roughly $14.96. With no single company-specific headline driving the session, markets attributed the move to pre-earnings de-risking, profit-taking after a strong rally, and a modest insider sale disclosure.
Pre-Earnings Positioning Weighs on Shares
The most immediate catalyst cited by traders is positioning ahead of Carlsmed's third-quarter 2026 results, due after the market close on November 10. Investors often reduce exposure in high-multiple, unprofitable growth names in the sessions before an earnings print, particularly when expectations have been rising. Carlsmed's second-quarter report showed revenue growth of 57% year over year to $18.94 million and prompted management to raise full-year guidance to a range of $74 million to $78 million. With the bar now higher, some holders appear to be locking in gains rather than carrying full positions into the report.
Profit-Taking After a Strong Rally
The pullback also reflects a classic bout of profit-taking. CARL climbed sharply over the prior six months and recently traded near its 52-week high of $17.23, supported by the U.S. commercial launch of its aprevo Lumbar Bi-lateral Posterior System and a series of bullish analyst notes, including a BTIG price-target increase to $24. After such gains, small-cap growth stocks are vulnerable to sharp reversals as momentum fades and investors rotate out of extended positions.
Insider Sale and Sentiment Signals
A secondary factor was a regulatory disclosure showing that Chief Operating Officer Jeffrey Bertolini sold 747 shares on November 3, executing an option exercise and selling the resulting shares for roughly $11,300. The transaction was small relative to the company's float and was conducted under a pre-arranged Rule 10b5-1 trading plan, but insider selling near a 52-week high can nonetheless dampen sentiment. The stock's elevated short interest—recently around 1.09 million shares—adds another layer of technical pressure, as downward moves in thinly traded small caps can feed on themselves.
Market Context and Trading Activity
Trading volume remained modest relative to the stock's roughly 108,000-share three-month average, suggesting a steady drift lower rather than a panic-driven liquidation. The decline was more pronounced than moves in the broader healthcare and small-cap complex, indicating company-specific positioning was the dominant driver. On the chart, the break below the 50-day moving average near $14.96 removed a key near-term support level, while the 200-day moving average near $12.44 remains a longer-term technical reference point for traders monitoring further downside.
What Comes Next for CARL
The near-term focus turns squarely to the November 10 earnings release. Investors will be scrutinizing revenue growth, surgeon user-base expansion, gross margin trends, and any revisions to full-year guidance, as well as the pace of adoption for the newly launched lumbar bi-lateral posterior system and cervical products. Analysts maintain a broadly bullish view, with a Strong Buy consensus and price targets ranging from $17 to $24. Key risks remain the company's widening net losses, elevated operating expenses, and competitive pressure from larger spine-device manufacturers. Until results arrive, shares may remain volatile as positioning resets.
Trending AI Robots
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a way to monitor automated approaches across different market environments. Explore the page to see which AI-driven strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for CARL turns positive, indicating new upward trend
CARL saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator turned positive. In 23 of the 25 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CARL's RSI Indicator exited the oversold zone, 4 of 5 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for CARL just turned positive on October 22, 2026. Looking at past instances where CARL's MACD turned positive, the stock continued to rise in 9 of 11 cases over the following month. The odds of a continued upward trend are 82%.
CARL moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CARL crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +6.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where CARL advanced for three days, in 59 of 72 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 14 of 17 cases where CARL's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
CARL broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CARL entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.706) is normal, around the industry mean (4.793). P/E Ratio (-6.214) is within average values for comparable stocks, (13.685). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.596) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. CARL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CARL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement